Abstract
In the treatment of multiple myeloma,bone metastatic tumor of malignant tumors and hypercalcemia, bisphosphonate (BP) administrates according to the BP injection formulation. Since the potency ratio of the bone through intravenous administration is higher than that of the oral medication, and due to the healing delay trendency and immunological deterioration from the effects of steroids and anti-cancer drugs used in the treatment of cancer,bisphosphonate-related osteonecrosis of the jaw(BRONJ) occurs in cancer patients at a high probability.The treatment for BRONJ of patients with cancer is often carried out conservatively, for first priority to suppression of the cancer , and life prognosis. However , the decision often deteriorates the quality of life of the patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
